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Primary immune thrombocytopenia 
in adults 
Guidelines for diagnosis and treatment anno 2013
proposed by the Belgian Hematological Society
A. Janssens, C. Lambert, G. Bries, A. Bosly, D. Selleslag, Y. Beguin
The Belgian Hematological Society (BHS) guideline panel on adult primary immune 
thrombocytopenia (ITP) reviewed the recent literature on diagnosis and treatment to 
make recommendations on the best strategies for frontline and subsequent-line treat-
ment. No treatment is necessary for patients with platelet counts higher than 30000/μl 
in the absence of bleeding symptoms. Patients newly diagnosed or relapsing after a 
long-term treatment-free period can be managed with corticosteroids with or without 
intravenous immunoglobulins. A second line therapy is indicated for those patients 
who are intolerant or unresponsive to or relapse after initial corticosteroid treatment 
and have a risk of bleeding. The guideline panel recommends splenectomy as it is the 
treatment with the highest curative potential and an acceptable safety pro le. If possible, 
splenectomy should be delayed to at least twelve months after diagnosis as spontaneous 
remission can occur in this time period. Thrombopoietin receptor (TPO-R) agonists are 
recommended for patients who are refractory to or relapse after splenectomy or who 
have a contra-indication to splenectomy irrespective of the duration of ITP. The guideline 
panel agrees that rituximab, azathioprine, cyclophosphamide, cyclosporine A, danazol, 
dapsone, mycophenolate mofetil and vincristine/vinblastine are potential treatment 
options, especially for patients refractory to TPO-R agonists.
(Belg J Hematol 2013;1:11-20)
Introduction with de nitions
Immune thrombocytopenia is an acquired autoim-
mune disease characterised by an isolated low 
platelet count number (<100,000/µl). The disorder 
is classifi ed as primary immune thrombocytopenia 
(ITP) in the absence of any obvious initiating and/
or underlying cause, and as secondary ITP in asso-
ciation with autoimmune disorders (systemic lupus 
erythematosus (SLE), the antiphospholipid syndrome 
(APS), etc.), some immunodefi ciency syndromes 
(CVID, adult lymphoproliferative syndrome, etc.), 
lymphoproliferative disorders (chronic lymphocytic 
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leukemia, Hodgkin’s disease, large granular T-lympho-
cyte proliferation, etc.), persistent infections (human 
immunodefi ciency virus, hepatitis C virus or H pylori) 
and vaccination.1,2 No reliable test exist that can be 
used to establish the diagnosis of ITP.
ITP can be further defi ned as newly diagnosed 
(lasting less than three months after diagnosis), 
persistent (lasting three to twelve months when 
spontaneous remission is not reached or complete 
response to therapy is not maintained) and chronic 
ITP (lasting for more than twelve months).1
Incidence
Data on epidemiology are limited. The incidence of 
newly diagnosed ITP among adults ranges from two 
to four per 100,000 persons per year.3 Due to the 
chronicity of the disease the prevalence goes up to 
±2 per 10,000 of the population. However ITP is 
still a rare disease and answers to the criteria of an 
orphan disease (prevalence <5/10000). 
ITP affect all age groups. In children the onset of 
ITP is typically abrupt and is frequently preceded 
by a febrile illness. Unlike adults, >70% of children 
with ITP have a normal platelet count one year 
after diagnosis.4
The incidence of ITP among men and women is 
generally similar except in middle age where women 
are more frequently affected.3
Pathogenesis
Increased understanding of the pathophysiology 
underlying ITP has shown that not only accelerated 
peripheral platelet destruction but also suppression 
of the production of new platelets can be responsible 
for the persistence of thrombocytopenia in several 
patients. Antibody loaded platelets bind to macro-
phages and dendritic cells and are removed by the 
reticulo-endothelial system (RES), primarily the spleen. 
More recently, it has been shown that platelets can 
also be destroyed by T-cells. Platelet production is 
frequently reduced because autoantibodies against 
platelet glycoproteins bind to megakaryocytes, inter-
fere with their maturation and lead to apoptosis. 
Besides, the level of thrombopoietin (TPO), the 
primary growth factor for the regulation of platelet 
production, in ITP is relatively low compared to patients 
with thrombocytopenia resulting from megakaryocytic 
hypoplasia. This means that the primary underlying 
mechanism may vary between patients, explaining 
why response to treatment also differs.5
Clinical presentation
Many patients remain asymptomatic with the diag-
nosis of ITP made only after a routine blood test. 
Others may have bleeding symptoms ranging from 
skin bleeding (petechiae, purpura, bruises [dry 
purpura]) to mucosal bleeding (gingival bleeding, 
mouth blisters, epistaxis, blood in stool or urine, 
heavy menstrual bleeding) or deep bleeding (intra-
cranial, abdominal bleeding, etc. [wet purpura]) 
appearing spontaneously or after trauma. Bleeding 
symptoms have mostly been reported in patients 
with a platelet count of less than 30,000/µl.5
Factors infl uencing the bleeding risk are age, comor-
bidities, lifestyle, need for invasive procedures, need 
of treatment with anticoagulant or antiplatelet 
agents, etc. 
Consequences
• Major impact on quality of life: at least as bad as 
patients with diabetes.6
• Effect on daily activities.5
• Burden on the healthcare system: higher costs, 
longer hospital admissions and higher in hospi-
tal mortality rate.5
Diagnostic work up2,7-11
• Personal history (prescription and non-prescrip-
tion drugs, alcohol abuse, consumption of quinine, 
recent transfusions,etc.).
• Familial history (excluding inherited thrombo-
cytopenias).
• Physical examination (with attention to node- 
bearing areas, including sizes of liver and spleen).
• A complete blood count with peripheral blood 
smear examination (exclude platelet aggregates 
(pseudothrombocytopenia), platelet aberrations, 
red and white cell abnormalities).
• Immunoglobulin levels (exclude CVID).
• Direct antiglobulin test with reticulocytes (exclude 
Evan’s syndrome).
• Coagulation tests (exclude DIC, Von Willebrand 
disease type 2).
• Blood group (for transfusion policy).
• Antinuclear factor, antiphospholipid antibodies, 
Belgian Journal of Hematology   Volume 4, Issue 1, March 2013
Practice Guidelines
4
lupus anticoagulant (exclude APS).
• Thyroid function, antithyroid antibodies (exclude 
thyroid dysfunction).
• Pregnancy test in women of child bearing potential 
(exclude gestational thrombocytopenia).
• Virology: Hepatitis C, HIV, HB.
• H pylori (antigen in stool or urea breath test).
• Bone marrow aspirate and biopsy (with immuno-
phenotyping and karyotyping) (in selected patients 
with abnormal physical examination (lymph-
adenopathy, organomegaly) or blood count or 
blood smear abnormalities and in patients >60 
years to exclude myelodysplasia or an indolent 
lymphoma).
• Chest radiograph (exclude chest disease).
• Abdominal ultrasound (exclude abdominal organ 
disease).
Additional work up before second-line 
treatment2,7-11
• Biological ﬁ tness (performance status (PS), and 
comorbidities (organ function).
• Bone marrow aspirate and biopsy (if not done 
previously, if no clear response to fi rst-line treat-
ment and before splenectomy).
Indications for initiation of treatment12
• Active bleeding OR platelets <10,000/µl
Treatment is obligatory.
• No or mild bleeding AND platelets 10-30,000/µl
Treatment is a potential option after evaluation 
of patient characteristics.
• No bleeding AND platelets >30,000/µl
No need for treatment unless special circum-
stances.
Treatment
Before initiating treatment consideration must be 
given to:
• Patient related factors such as age, PS, comorbidi-
ties, life style (sedentary versus active) and patient 
wishes.
• Disease related factors such as platelet count 
and previous major bleeding.
• Additional risk factors for bleeding such as the use 
of antiplatelet and anticoagulant agents, uremia, 
poorly controlled hypertension, aneurysm, fever, 
chronic liver disease, history of peptic ulcer, etc.
• Treatment related factors such as expected re-
sponse, contraindications to and side-effects 
from particular treatment modalities. 
• The need of medical intervention that may cause 
bleeding (Table 1).7
• Easy access to care facilities.
The main treatment goal in all ITP patients must be 
to maintain a safe platelet count to prevent or stop 
bleeding and not to normalize the platelet count, 
to decrease activity restrictions and improve quality 
of life with a minimum of exposure to potentially 
toxic therapy.12
When is hospitalisation for ITP justi ed?
The decision to hospitalise a patient with ITP is 
based primarily on the haemorrhage situation 
(patients with signs of mucosal or deep bleeding 
are frequently admitted) and on factors infl uencing 
the bleeding risk (age, comorbidities, need for treat-
ment with anticoagulant or antiplatelet agents, etc.). 
Table 1.  Safe platelet count for medical 
interventions in patients with 
platelet production problems7
Dentistry ≥ 10 to 20 x 0000/μl
Extractions (simple) ≥ 30 x 0000/μl
Extractions (complex, molar ≥ 50 x 0000/μl
Lumbar puncture ≥ 50 x 0000/μl
GI endoscopy with biopsy ≥ 20 x 0000/μl
Bronchoscopy ≥ 20 x 0000/μl
(≥ 50 if also biopsy)
Organ biopsy ≥ 50 x 0000/μl
(<for bone marrow biopsy)
Minor surgery ≥ 50 x 0000/μl
Major and neurosurgery ≥ 80 x 0000/μl
Epidural anesthesia ≥ 80 x 0000/μl
(No equivalent data are available for ITP patients, 
the individual bleeding history must be considered)
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Treatment of newly diagnosed ITP
Newly diagnosed ITP patients are managed with 
corticosteroids with or without intravenous immu-
noglobulins (IVIg) depending on the severity of 
thrombocytopenia and/or of bleeding signs and 
symptoms. Although impressive responses are seen 
using these therapeutic agents, these responses 
are usually short lived. Thus, in adults, ITP is very 
frequently characterised by relapses upon tapering 
or discontinuation of treatment, requiring repeated 
courses of medical intervention.2,7-10
Characteristics of treatment with corticosteroids 
and IVIg are shown in Tables 2 and 3.
Platelet transfusions are only indicated in case of 
life-threatening bleeding together with the adminis-
tration of corticosteroids and IVIg. 
Treatment of persistent ITP (lasting 3 to 
12 months after diagnosis) and chronic 
ITP (lasting >12 months after diagnosis)
Indications for the start of treatment in persistent 
and chronic ITP are identical to those of newly 
diagnosed ITP.
Relapse after a long treatment free interval can be 
managed by restarting fi rst line treatment being 
steroids with or without IVIg.2,7-10 A long-term steroid 
treatment must be avoided, although in some 
patients a long-term treatment with steroids under 
Table 2.  Characteristics of treatment with 
corticosteroids 
• No preference to choose prednisone, (methyl)
prednisolone (dexamethasone is also an option). 
• Starting dose: 0.5 to 2 mg/kg/d predniso(lo)ne or 
equivalent.
• Full dose for 7-14 d.
• Tapering: slow tapering during the following two to three 
months if responsive, rapid tapering if not responsive.
• Short term response: 75-80%.
• Durable response: <30%.
• Mode of action: impairs antibody formation, antibody 
binding by platelets and clearance of antibody loaded 
platelets by RES, increase thrombopoiesis, improves 
hemostasis, etc.
• Side effects: changing facial and body features, skin 
fragility, arterial hypertension, myopathy, diabetes 
mellitus (DM), psychological problems, osteoporosis, 
osteonecrosis, cataract, glaucoma, etc.
• More side effects compared with other therapies leading 
to dose reduction and treatment discontinuation.
• Absolute contraindication for steroids: acute viral infection 
(Herpes Simplex virus, Herpes Zoster virus, etc.), 
HBsurface Ag positive chronic active hepatitis.
• Relative contraindication for steroids: peptic ulcera, 
bacterial infections, tuberculosis, mycoses, parasitosis, 
uncontrolled hypertension, DM, osteoporosis, psychosis, 
glaucoma, and recent enteroanastomosis.
• Cheap.
Table 3.  Characteristics of treatment with 
immunoglobulins
• Start dose: 400 mg/kg/d for  ve days or 1 g/kg/d for one 
or two days. 
• Short term response: ± 80%, rapid response.
• Durable response: only in few patients, relapse between 
14-28d.
• Repeated infusions possible.
• Mode of action: impairs clearance of antibody loaded 
platelets by macrophages, impairs B cell function, 
increases T suppressor cells.
• Side effects: infusion related, headache, aseptic 
meningitis, renal impairment (only for preparations 
containing sucrose).
• Expensive.
Table 4.  Second and subsequent treatment 
options for relapsing and refractory 
adult ITP
Retreatment options
Corticosteroids Prednisone or equivalent: 
0,5-2mg/kg/d po
Dexamethasone: 40mg/d x 4d q 
14-28d, 4-6 courses po 
Immunoglobulins 400mg/kg/d x5d or 
1g/kg/d x1-2d IV
Second- or further line treatment options
Splenectomy
TPO-R agonists
Romiplostim 1-10 μg/kg/wk sc 
Eltrombopag 25-75 mg/d po 
Rituximab
375 mg/m2/wk for 4wks or 100 mg/wk for 4wks IV
Other options (listed alphabetically Table 4 bis) 
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the Cushing-threshold (<5 mg prednisone/day or 
equivalent) with close monitoring of adverse events 
can be considered.7
A second line therapy is indicated for those patients 
unresponsive to, relapsing during or shortly after 
tapering of steroids (Table 4). Immunoglobulin ad-
ministration is a valuable treatment option especially 
if a fast platelet increase is to be achieved. However 
the chance to achieve a durable response after IVIg 
is low.2,7-10
For decades, splenectomy has been the standard 
management for ITP patients with persistent low 
platelets and a high bleeding risk, unresponsive or 
intolerant to corticosteroids. Two-thirds of patients 
attain a durable remission. Morbidity and mortality 
of laparoscopic splenectomy are low in the hands 
of experienced surgeons. The incidence of over-
whelming sepsis is reduced with recommended 
vaccination protocols and antibiotics initiated at 
fi rst sign of a systemic febrile illness. However, physi-
cians and patients frequently opt to postpone the 
removal of this healthy organ.2,7-10 As spontaneous 
remission of ITP up to twelve months after diagnosis 
can occur in adults, an attempt should be made to 
delay splenectomy until after this point.13 Charac-
teristics of splenectomy with the relative contraindi-
cations for surgery are shown in Tables 5 and 6.
Azathioprine, cyclophosphamide, cyclosporine A, 
danazol, dapsone, mycophenolate mofetil and 
vincristine have been used after treatment failure 
in both splenectomised and non-splenectomised 
patients for decades. These treatment options are 
characterised by variable individual responses after 
days, weeks to months and signifi cant long-term 
side effects such as immune suppression (except for 
danazol and dapsone), which must be considered 
by patient and physician.2,7-10 Some characteristics 
of these agents are shown in Table 4.
Rituximab has been used for treating relapsing 
and refractory ITP patients for almost ten years. 
Randomised controlled trials are not available to 
establish optimal dose, schedule and timing of ritux-
imab administration and to confi rm effi cacy and 
reveal long-term safety. For these reasons, rituximab 
has still no license for treating ITP.14 In systematic 
reviews however a favourable overall response rate 
of approximately 60% with a complete response 
rate of 40% was estimated.15 Responses seem com-
parable for splenectomised and non-splenectomised 
patients. A median duration of response of approxi-
mately six and twelve months was observed for 
partial and complete responders, respectively.15-16 
Twenty-one percent of adult chronic ITP patients 
maintained a treatment-free response for at least 
fi ve years after treatment with standard-dose ritux-
imab without major toxicity.17
The second-generation thrombopoietic agents 
(romiplostim and eltrombopag) have confi rmed the 
hypothesis that stimulating platelet production is a 
valid treatment approach in ITP. TPO-Receptor (R) 
agonists have been associated with more durable 
Table 4 bis.  Other options (listed alphabetically)
Dose Toxicities
Azathioprine 1-2 mg/kg/d po Neutropenia, transaminase elevation, pancreatitie, etc.
Cyclophosphamide 1-2 mg/kg/d po
500-1000 mg 4wks IV
Nausea, vomiting, sterility, secondary acute myeloid leukemia, 
etc.
Cyclosporine 4-5 mg/kg/d po (through blood 
levels 100-200 ng/ml)
Renal insuf ciency, hypertension, neuropathy, hypertrichosis, 
tremor, gingival hyperplasia, etc.
Danazol 400-800 mg/d po Weight gain, hair loss, liver dysfunction, myalgia, amenorrhea, 
etc.
Dapsone 75-100 mg/d po Abdominal distension, anorexia, nausea, hemolytic anemia if 
glucose 6-phosphate dehydrogenase de ciency, etc.
Mycophenolate 
mofetil
1000 mg bid po Headache, anorexia, nausea, abdominal distention, etc.
Vincristine 1-2 mg/wk IV max for 6 wks Neuropathy, constipation, hair loss, etc.
Vinblastine 5-10 mg/wk IV max for 6 wks Neuropathy, constipation, hair loss, etc.
27
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platelet responses and less treatment failure com-
pared to placebo or standard of care (SOC) in adult 
chronic (defi ned in all trials as ITP lasting >6 mo) 
ITP patients, regardless of splenectomy status.18-20 
Effi cacy data seem identical for patients included 
with acute or persistent ITP.21 The response rates 
obtained in the pivotal studies were reproduced in 
open-label studies even when patients with severe 
comorbidities and older age were enrolled.18,19,22 
Patients relapsing after or refractory to rituximab 
seem to be as responsive as cohorts where previous 
exposure to rituximab was lower.22 Treatment with 
TPO-R agonists results in a reduction of bleeding 
events, in less use of rescue medication or splenec-
tomy and permits the majority of patients receiving 
concurrent ITP drugs to reduce or discontinue 
these therapies and avoid further immunosuppres-
sion (Table 7).18,19 An additional role of the TPO-R 
agonists may be to use the drug intermittently 
around the time of an anticipated bleeding risk. 
TPO-R agonists are very well tolerated. However, 
due to the fact that experience with TPO-R agonists 
in the clinic does not exceed seven years, a high 
index of suspicion for possible risks of long-term 
use of TPO-R agonists is warranted (Table 8). In ad-
dition, the cost of treating a patient for several 
months or even years may be considerable.
In Belgium, the TPO-R agonists, romiplostim and 
eltrombopag, are reimbursed for the treatment of 
chronic adult ITP patients (ITP lasting >12 mo) 
refractory or intolerant to corticosteroids after 
splenectomy or when surgery is contraindicated.
For adult ITP patients who are intolerant or unre-
sponsive to or relapse after initial corticosteroid 
treatment and have a risk of bleeding (platelets 
<30000/µl OR bleeding symptoms), the BHS 
guideline panel on adult ITP:
1:  Recommends
- Splenectomy as it is the only treatment with a 
curative potential and has an acceptable safety 
profi le. If possible, splenectomy should be delayed 
to at least twelve months after diagnosis as spon-
taneous remission can occur in this time period.
- TPO-R agonists for patients who are refractory 
to or relapse after splenectomy or who have a 
contra-indication to splenectomy irrespective of 
the duration of ITP. 
2:  Suggests
- Rituximab, azathioprine, cyclophosphamide, 
cyclosporine A, danazol, dapsone, mycophenolate 
Table 5.  Characteristics of splenectomy 
in adult ITP
Most effective durable treatment for adults
(± 66% long-term normal platelets, ± 14% no response, 
± 20% late failures)
Laparoscopic splenectomy: less postoperative pain, 
less infectious complications, earlier diet tolerance, shorter 
hospital stay but more hemorrhagic complications compared 
to open splenectomy
No preoperative characteristic can reliably predict success 
of splenectomy (111In platelet survival: if only splenic 
sequestration, 90% responders; less response if platelets 
very low, more than 3 previous treatments, elderly)
Perioperative complications: (comparable to other minor 
surgical procedures and general anesthesia)
Mortality 1% for laparotomy 
0.2% for laparoscopy
Morbidity 13% for laparotomy 
10% for laparoscopy 
Acute venous thromboembolism: low but increased 
frequency (appropriate thrombosis prophylaxis postoperative 
especially when risk factors for thrombosis present, 
acetylsalicylic acid (ASA) if platelets >500,000/μl)
Acute portal vein thrombosis: can occur in the  rst three 
months; range from asymptomatic to fatal; higher after 
laparoscopy; start diagnostic investigations in patients with 
cramping abdominal pain, depressed bowel sounds and 
generalized bowel tenderness 
Long-term effects
Overwhelming post-splenectomy infection (OPSI) (mostly 
Streptococcus (S) pneumoniae, Neiseria (N) meningitidis, 
Haemophilus (H) In uenzae but also E. Coli, Capnocytophagia 
canimorsus, group B streptococcus, Ehrlichia and plasmodium 
spp (cavé travellers!)
Appropriate and timely (2 to 4wks before or otherwise 2wks after 
splenectomy) immunization against:
• S. pneumoniae i.e. Prevenar 13®, 1 injection.
• N. meningitidis i.e. Meningitec®, Menjugate® 
or Neisvac-C®, 1 injection.
• H. In uenzae i.e. ActHib®, 1 injection.
Annual  u vaccine.
Education of patient regarding risk of overwhelming infection. 
Prompt treatment of infection life-long!
Cost: in most countries affordable.
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mofetil and vincristine/vinblastine are potential 
treatment options, especially for patients refrac-
tory to TPO-R agonists.
ITP in pregnancy25,26
ITP is an uncommon but important cause of throm-
bocytopenia in pregnancy. Disorders that can cause 
thrombocytopenia in non-pregnant women must of 
course be excluded (drug-, viral-induced thrombo-
cytopenia, ITP secondary to SLE or APS, etc.). Other 
causes of thrombocytopenia specifi c for the setting 
of pregnancy are gestational thrombocytopenia, 
microangiopathic thrombotic syndromes, preeclamp-
sia, HELLP (hemolysis, elevated liver enzymes, low 
platelet count) syndrome and acute fatty liver of 
pregnancy. These disorders must be separated from 
ITP because their successful management differs 
completely from the management of ITP (Table 9). 
Pregnant women with ITP require careful moni-
toring (monthly till week 28, every two weeks till 
week 36, weekly till delivery). The indications for 
treatment of the pregnant woman do not differ from 
those of a non-pregnant person. However, a platelet 
count of 50,000/µl is recommended for vaginal 
delivery and caesarean section and a platelet count 
of 80,000/µl is recommended for epidural anesthe-
sia. If treatment is necessary prednisone 1 mg/kg/d 
(pre-pregnancy weight) or equivalent can be started 
and gradually titrated to the lowest effective dose 
(avoid high doses in fi rst trimester to prevent con-
genital anomalies and prolonged high doses because 
of exaggerated toxicity during pregnancy). IVIg are 
also considered as an appropriate fi rst-line treatment 
Table 6.  Relative contraindications 
for splenectomy
Platelet count <20,000/μl before surgery (platelets 
>20,000/µl are ideal to limit the risk of 
postoperative bleeding, to minimize trauma 
to upper airway during general anesthesia).
Geriatric patient
Comorbidities Uncontrolled diabetes mellitus








Table 7.  Characteristics of treatment with 
TPO-R agonists
Dosing of TPO-R agonists
Romiplostim 23
• Start with 1 μg/kg/wk sc.
• Increase dose by 1 μg/kg/wk if platelet count 
<50,000/μl till a maximum dose of 10 μg/kg/wk.
• Maintain dose if platelet count between 50 and 
150,000/μl.
• Reduce dose by 1 μg/kg/wk if platelet count between 
150 and 250,000/μl for two weeks.
• Stop dosing and reassess after 1 week if platelet 
count >250,000/μl and restart dosing with -1 μg/kg/
wk if platelet count <150,000/μl.
• If platelet count ≥ 50,000/μL for at least four weeks 
without dose adjustment, assess platelet count once 
monthly. 
• Consider to administer romiplostim at home (nurse, 
self-administration). 
Eltrombopag 24
• No intake of calcium, iron, magnesium, aluminium 
rich food 4h before and after ingestion. 
• Start with 50 mg once daily po.
• If platelet count <50,000/μl after 2 weeks, increase 
dose to 75 mg once daily.
• If platelet count between 50 and 150,000/μl, 
maintain dose.
• If platelet count between 150 and 250,000/μl, 
reduce to 25 mg once daily.
• If platelet count >250,000/μl, stop dosing, monitor 
platelet count twice weekly and reinitiate at a daily 
dose reduced by 25 mg if platelet count <100,000/μl.
• If platelet count ≥50,000/μL for at least 4 weeks 
without dose adjustment, assess platelet count once 
monthly. 
TPO-R agonists induce durable platelet responses 
(60% stable responses, 25% variable responses, 
15% minor or no response) and less treatment failures 
regardless of splenectomy status, response to rituximab 
and duration of ITP.
TPO-R agonists reduce the need of rescue medication 
(IVIg, splenectomy) and permit to reduce or discontinue 
concurrent ITP drugs (corticosteroids, etc.) and avoid 
further immunosuppression. 
TPO-R agonists reduce bleeding events. 
TPO-R agonists improve health-related quality of life. 
TPO-R agonists are very well tolerated.
Expensive. 
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for ITP during pregnancy. Patients who fail to respond 
to corticosteroids or IVIg alone may respond to the 
combination of these agents. Laparoscopic splenec-
tomy can be safely performed in the second trimester 
with an estimated remission rate of 75%. Splenectomy 
is not recommended in the fi rst trimester due to the 
risk of induction of premature labor or in the third 
trimester due to bad visualisation of the surgical 
fi eld. Azathioprine and rituximab have been used in 
pregnant women but immunosuppression can be 
seen in the neonates. The experience with TPO-R 
agonists during pregnancy is minimal. This treat-
ment should only be considered if the potential 
beneﬁ t to the mother justiﬁ es the potential risk to 
the fetus. A pregnancy registry has been established 
to collect information about the effects of TPO-R 
agonists during pregnancy. There is no correlation 
between platelet count of the mother and the 
Table 9.  Thrombocytopenia 
in pregnancy25,26
ITP 
• diagnosis of exclusion (exclude secondary ITP 
especially SLE and APS)
• more likely if history of thrombocytopenia before 
pregnancy 
• may present at any time during pregnancy 
• serial platelet counts should be obtained in the 
newborns at birth and in the  rst week postpartum
Gestational thrombocytopenia 
• platelets mostly >70000/µl
• develops in the late second and third trimester
• not associated with an increase in maternal or fetal 
complications, newborn not at risk for developing 
thrombocytopenia
Preeclampsia
• arterial hypertension (systolic >140 and/or diastolic 
blood pressure >90mm Hg), proteinuria (>300 mg/24h) 
and thrombocytopenia in 50% of patients
• thrombocytopenia may precede other signs
• develops after twenty weeks of gestation 
• delivery of the fetus after stabilization of the mother 
• platelet transfusions in the setting of severe 
thrombocytopenia and bleeding
HELLP syndrome
• nausea, malaise, upper right quadrant pain or 
epigastric pain, microangiopathic hemolytic 
anemia, abnormal liver function (OT >70U/L) and 
thrombocytopenia 
• most frequent in third trimester
• delivery of the fetus after stabilization of the mother
• platelet transfusions in the setting of severe 
thrombocytopenia and bleeding 
Thrombotic thrombocytopenic purpura (TTP) and 
hemolytic uremic syndrome (HUS)
• microangiopathic hemolytic anemia, thrombocytopenia, 
neurologic abnormalities, fever and renal dysfuction 
(neurological changes more pronounced in TTP and 
renal changes in HUS)
• TTP most frequent in the second trimester
• 90% of HUS appears in the postpartum period
• plasma exchange
Acute fatty liver of pregnancy
• malaise, anorexia, nausea, vomiting, epigastric or 
right upper quadrant pain, mental status changes and 
cholestatic liver abnormalities with DIC 
• typically in primipara in the third trimester
• delivery of the fetus after stabilisation of the mother
Table 8.  Possible risks of long-term use 
of TPO-R agonists
Loss of ef cacy with prolonged stimulation of 
megakaryopoiesis.
Bone marrow  brosis
• Follow up of blood cell count and smear monthly
• If loss of response, new cytopenia or new morphologic 
abnormalities, a bone marrow biopsy should be done
Thrombosis 
• Thrombotic event rate identical with TPO-R agonists, 
placebo or SOC 
• Thrombosis not correlated with high platelet counts
More severe thrombocytopenia after drug 
discontinuation (10%)
Neutralizing antibody formation
• A few patients with anti-romiplostim AB but without 
loss of response; 
• Eltrombopag is not immunogenic
Hepatotoxicity (10% of patients on eltrombopag develop 
elevated liver enzymes)
• Control of liver function before and each 2 weeks 
during titration and monthly following achievement 
of a stable dose
Cataract
• Recommended to do an ophtalmologic examination 
before and annually during eltrombopag treatment 
Induction of malignancy (not an issue in ITP)
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newborn. The most reliable predictor of neonatal 
thrombocytopenia is a history of low platelet count 
at delivery in a prior sibling. Platelet counts <20,000 
and <50,000/µl were seen in respectively 4 and 10% 
of neonates. Neonatal intracranial hemorrhage was 
seen in <1% and was not associated with the mode of 
delivery. Therefore, the mode of delivery in pregnant 
ITP patients should be solely dictated by maternal 
factors. There is no place for fetal scalp vein sam-
pling or percutaneous umbilical blood sampling 
to predict the platelet count of the newborn. After 
delivery serial platelet counts should be obtained 
in the newborns at birth and in the fi rst week post-
partum as the onset of thrombocytopenia due to 
maternal antiplatelet antibodies may be delayed.
Supportive treatment 
• Antiﬁ brinolytic agents
• Oral iron supplements if iron deﬁ cient.
• Local application of adrenalin soaked nose pads.
• Nasal cautery.
• Hormone preparations to prevent menorrhagia.
• Control of blood pressure.
• Stop ASA, antiplatelet agents, anticoagulation if 
appropriate: except in case of recent stent, ischemic 
heart disease, severe peripheral arterial occlu-
sive disease.
• Avoid nonsteroidal anti-inﬂ ammatory drugs or ASA.
Conclusion 
The main treatment goal in all ITP patients must be 
to achieve a safe platelet count to prevent or stop 
bleeding and to decrease activity restrictions and 
improve quality of life with a minimum of exposure 
to potentially toxic therapy. The BHS guideline panel 
on adult ITP reviewed the recent literature on diag-
nosis and treatment and has made recommenda-
tions on the best strategies for frontline and subse-
quent-line treatment. However, the pros and cons of 
each treatment option must be discussed in a per-
sonalised way with each patient. Psychosocial and 
medical factors as patient’s goals, fears, family sup-
port, proximity to medical care, comorbidities, 
compliance, tolerance of each approach have to be 
considered in addition to outcomes. 
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